160 College Street, Toronto, Ontario M5S 3E1, Canada
Product Features & Capabilities
Injectable hydrogel platform
AMT-143 for non-opioid pain management
Advanced sustained release formulations
Other Considerations
Closed CAD$4.0 million Series A extension; Exclusive global licensing agreement with Pacira BioSciences; Dosed first human subject with AMT-143; Featured in RBCx media coverage